Effect of cadmium on the peripheral kynurenine pathway in rats

• Autorzy: Pawlak D , Brzoska M. , Moniuszko-Jakoniuk J. , Stypulkowska A. , Zwierz K.
• Języki publikacji: EN

Abstrakty

EN

This study investigated the kynurenine metabolism in rats treated with cadmium. We used an animal model at the levels of Cd corresponding to human environmental and occupational exposure to this metal which allows the assessment of its early effect on the structure and function of kidneys. We observed significant decrease in the serum concentration of tryptophan (TRP) and its metabolites: kynurenine (KYN), kynurenic acid (KYNA), and 3-hydroxykynurenine (3-HKYN), which was accompanied by a decrease in KYN derivatives in kidney and liver tissues. This effect was dependent on the level of Cd exposure. Regression analysis showed negative correlations between blood concentrations of Cd and TRP derivatives in serum, kidney and liver tissues. Conversely, the urinary concentration of KYN and KYNA increased. Changes in product degradation of TRP after Cd treatment were proportional to the severity of renal damage and correlated with the concentration of proximal tubular injury marker — urinary isoenzyme B of N-acetyl-D-glucosaminidase (NAG-B). Our results seem to indicate that intoxication with Cd induced significant disturbances in the peripheral kynurenine pathway.

Słowa kluczowe

EN

kynurenine; 3-hydroxykynurenine; kynurenic acid; cadmium; kidney; tryptophan; toxicology; liver; rat

• Wydawca: -
• Czasopismo: Polish Journal of Environmental Studies
• Rocznik: 2005
• Tom: 14
• Numer: 4
• Opis fizyczny: p.501-507,fig.,ref.

Twórcy

autor

Pawlak D

• Medical University, Mickiewicza 2C, 15-230 Bialystok, Poland

autor

Brzoska M.

autor

Moniuszko-Jakoniuk J.

autor

Stypulkowska A.

autor

Zwierz K.

Bibliografia

• 1. STONE T. W. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog. Neurobiol. 64, 185, 2001.
• 2. STONE T. W., MACKAY G. M., FORREST C. M., CLARK C. J., DARLINGTON L. G. Tryptophan metabolites and brain disorders. Clin. Chem. Lab. Med. 41, 852, 2003.
• 3. TOPCZEWSKA-BRUNS J., PAWLAK D., TANKIEWICZ A., CHABIELSKA E., BUCZKO W. Kynurenine metabolism in central nervous system in experimental chronic renal failure. Adv. Exp. Med. Biol. 527, 77, 2003.
• 4. KLIVENYI P., TOLDI J., VECSEI L. Kynurenines in neurodegenerative disorders: therapeutic consideration. Adv. Exp. Med. Biol. 541, 169, 2004.
• 5. MOFFETT J. R., NAMBOODIRI M. A. Tryptophan and the immune response. Immunol. Cell Biol. 81, 247, 2003.
• 6. ZSIZSIK B. K., HARDELAND R. Formation of kynurenic and xanthurenic acids from kynurenine and 3-hydroxykynurenine in the dinoflagellate Lingulodinium polyedrum: role of a novel, oxidative pathway. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 133, 383, 2002.
• 7. BROWN R. R., OZAKI Y., DATTA S. P., BORDEN E. C., SONDEL P. M., MALONE D. G. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 294, 425, 1991.
• 8. ALLEGRI G., COSTA C., BACCICHETTI F., BIASIOLO M. Effects of two different loading doses of Ltryptophan on the urinary excretion of tryptophan metabolites in rats, mice and guinea pigs. Correlation with the enzyme activities. Ital. J. Biochem. 36, 194, 1987.
• 9. TANKIEWICZ A., PAWLAK D., TOPCZEWSKA-BRUNS J., BUCZKO W. Kidney and liver kynurenine pathway enzymes in chronic renal failure. Adv. Exp. Med. Biol. 527, 409, 2003.
• 10. HAC E., KRZYZANOWSKI M., KRECHNIAK J. Cadmium content in human kidney and hair in the Gdansk region. Sci. Total. Environ. 224, 81, 1998.
• 11. ROELS H. A., HOET P., LISON D. Usefulness of biomarkers of exposure to inorganic mercury, lead, or cadmium in controlling occupational and environmental risk of nephrotoxicity. Renal. Fail. 21, 251, 1999.
• 12. MITSUMORI K., SHIBUTANI M., SATO S., ONODERA H., NAKAGAWA J., HAYASHI Y., ANDO M. Relationship between the development of hepato-renal toxicity and cadmium accumulation in rats given minimum to large amounts of cadmium chloride in the long-term: preliminary study. Arch. Toxicol. 72, 545, 1998.
• 13. MONIUSZKO-JAKONIUK J., PAWLAK D., BRZOSKA M. M. Exposure to cadmium and tryptophan metabolism. Toxicol. Lett. 123, 48, 2001.
• 14. MONIUSZKO-JAKONIUK J., PAWLAK D., BRZOSKA M. M. Search of new markers of cadmium exposure. Toxicology B, 66, 2001.
• 15. PAWLAK D., TANKIEWICZ A., BUCZKOW. Kynurenine and its metabolites in the rat with exerimental renal insufficiency. J. Physiol. Pharmacol. 52, 755, 2001.
• 16. PAWLAK D., TANKIEWICZ A., MYSLIWIEC M., BUCZKO W. Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure. Nephron 90, 328, 2002.
• 17. PAWLAK D., TANKIEWICZ A., MATYS T., BUCZKO W. Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure. J. Physiol. Pharmacol. 54, 175, 2003.
• 18. GILES A. R. Guidelines for the use of animals in biomedical research. Thromb. Haemost. 58, 1078, 1987.
• 19. ZWIERZ K., GINDZIEŃSKI A., GŁOWACKA D., POROWSKI T. The degradation of glycoconjugates in the human gastric mucous membrane. Acta Med. Acad. Sci. Hung. 38, 145, 1981.
• 20. HEVERE C., BEYNE P., JAMAULT H., DELACOUX E. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J. Chromatogr. 675, 157, 1996.
• 21. HOLMES E. W. Determination of serum kynurenine and hepatic tryptophan dioxygenase activity by high liquid chromatography. Anal. Biochem. 172, 518, 1988.
• 22. HEYES E. P. Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electrochemical detection. J. Chromatogr. 428, 340, 1988.
• 23. HOLMES E. W., KAHNST. T. Tryptophan distribution and metabolism in experimental chronic renal insufficiency. Exp. Mol. Pathol. 46, 89, 1987.
• 24. SAITO K., FUJIGAKI S., HEYES M. P., SHIBATA K., TAKEMURA M., FUJII H., WADA H., NOMA A., SEISHIMA M. Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency. Am. J. Physiol. Renal. Physiol. 279, F565, 2000.
• 25. PAWLAK D., PAWLAK K., MALYSZKO J., MYSLIWIEC M., BUCZKO W. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int. Urol. Nephrol. 33, 399, 2001.
• 26. PAWLAK D., KODA M., PAWLAK S., WOLCZYNSKI S., BUCZKO W. Contribution of quinolinic acid in the development of anemia in renal insufficiency. Am. J. Physiol. Renal. Physiol. 284, F693, 2003.